An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
Completed
Clinical Trial Data Services, Inc.
Phase 1
2019-12-02
This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous
infusions of Furoscix.
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
Completed
CSSi Life Sciences
Phase 1
2019-12-02
This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous
infusions of Furoscix.
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
Completed
scPharmaceuticals, Inc.
Phase 1
2019-12-02
This is a Phase 1 study to evaluate the safety and tolerability of shortened subcutaneous
infusions of Furoscix.
Furoscix in Heart Failure Patients With Diuretic Resistance
Not yet recruiting
scPharmaceuticals, Inc.
Phase 2
2022-10-01
This will be a randomized, open-label pilot study of 60 patients with and without diuretic
resistance who were recently admitted and discharged for acute decompensated heart failure
with and oral furosemide regimen testing whether Furoscix is more effective at achieving
post-discharge outpatient diuresis than standard of care. Diuretic resistance will be
identified using the BAN-ADHF (BUN, creAtinine, NP-levels, Age, Diabetes and DBP, HF
hospitalization, and atrial Fibrillation) score which has been integrated into the electronic
health record. The score is integer-based with a score of > 11 indicating diuretic resistance
with high likelihood of poor outcomes. The primary outcome is spot urine sodium at 1 hour, 4
hours, and 8 hours post-treatment.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
